A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).

The discovery of purine nucleoside phosphorylase (PNP) deficiency and T lymphocytopenia suggested that inhibition of this enzyme could serve as a therapeutic target. Inhibitors of PNP failed until structure-based synthesis of immucillin-H (BCX-1777, forodesine), a transition-state analog of PNP. The picomolar potency for PNP, T cell-selective cytotoxicity, and animal studies provided the rationale for use of forodesine in T-cell malignancies. Five patients were treated with an intravenous infusion of forodesine (40 mg/m2) on day 1; treatment continued on day 2; forodesine was administered every 12 hours for an additional 8 doses. Plasma and cellular pharmacokinetics and pharmaco-dynamics were investigated. Median peak level of forodesine (5.4 microM) was achieved at the end of infusion. This level was sufficient to increase plasma 2'-deoxyguanosine (dGuo) concentrations in all patients. Intracellular deoxyguanosine triphosphate (dGTP) increased by 2- to 40-fold in 4 of 5 patients (8 of 9 courses) and correlated with antileukemia activity in 4 patients. However, objective responses were not observed. This was the first clinical study in humans to demonstrate the plasma pharmacokinetics and the pharmacodynamic effectiveness of the PNP inhibitor, forodesine; however, regrowth of leukemia cells in the blood and marrow after course 1 suggested that a different therapeutic schedule should be considered for future studies.

[1]  F. Foss,et al.  Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Patients with Refractory Cutaneous T-Cell Lymphoma. , 2004 .

[2]  V. Gandhi,et al.  Antileukemic Activity and Pharmacodynamics of Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, in Phase I/II Trials in Patients with Advanced T-Cell Malignancies. , 2004 .

[3]  V. Gandhi,et al.  Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Phase I/II Studies in Patients with B-Cell Acute Lymphoblastic Leukemia. , 2004 .

[4]  Walter Filgueira de Azevedo,et al.  Crystal structure of human purine nucleoside phosphorylase complexed with acyclovir. , 2003, Biochemical and biophysical research communications.

[5]  S. Bantia,et al.  Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777. , 2003, International immunopharmacology.

[6]  Y. Babu,et al.  Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2'-deoxyguanosine in primates. , 2003, International immunopharmacology.

[7]  V. Schramm.  Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents. , 2002, Biochimica et biophysica acta.

[8]  G. Evans,et al.  Addition of lithiated 9-deazapurine derivatives to a carbohydrate cyclic imine: convergent synthesis of the aza-C-nucleoside immucillins. , 2001, The Journal of organic chemistry.

[9]  J. Montgomery,et al.  Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent. , 2001, International immunopharmacology.

[10]  R. Furneaux,et al.  Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[12]  G. Evans,et al.  Synthesis of transition state analogue inhibitors for purine nucleoside phosphorylase and N-riboside hydrolases , 2000 .

[13]  G. Omura,et al.  Pharmacokinetics and Pharmacodynamics of Peldesine (BCX‐34), a Purine Nucleoside Phosphorylase Inhibitor, following Single and Multiple Oral Doses in Healthy Volunteers , 2000, Journal of clinical pharmacology.

[14]  S. P. Walton,et al.  Synthesis and Biological Activity of a Novel Class of Purine Nucleoside Phosphorylase Inhibitors , 2000, Nucleosides, nucleotides & nucleic acids.

[15]  W. Saenger,et al.  Crystal structure of the purine nucleoside phosphorylase (PNP) from Cellulomonas sp. and its implication for the mechanism of trimeric PNPs. , 1999, Journal of molecular biology.

[16]  H. Kantarjian,et al.  Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Turner,et al.  Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells. , 1998, Immunopharmacology.

[18]  R. Furneaux,et al.  One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. , 1998, Biochemistry.

[19]  C. Mao,et al.  The crystal structure of Escherichia coli purine nucleoside phosphorylase: a comparison with the human enzyme reveals a conserved topology. , 1997, Structure.

[20]  Xiaodong Wang,et al.  Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c , 1996, Cell.

[21]  P. Thall,et al.  Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.

[22]  V. Schramm,et al.  Pre-steady-state transition-state analysis of the hydrolytic reaction catalyzed by purine nucleoside phosphorylase. , 1995, Biochemistry.

[23]  V. Schramm,et al.  Purine nucleoside phosphorylase. Catalytic mechanism and transition-state analysis of the arsenolysis reaction. , 1993, Biochemistry.

[24]  M. Erion,et al.  Purine nucleoside phosphorylase inhibitors: biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds. , 1993, Journal of Pharmacology and Experimental Therapeutics.

[25]  R. Gilbertsen,et al.  Comparative in vitro and in vivo activities of two 9-deazaguanine analog inhibitors of purine nucleoside phosphorylase, CI-972 and PD 141955. , 1992, Biochemical pharmacology.

[26]  J. A. Fyfe,et al.  Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. , 1989, Analytical biochemistry.

[27]  R. Lewis,et al.  Phosphorylation of deoxyguanosine in intact and fractured mitochondria , 1987, Molecular and Cellular Biochemistry.

[28]  R. Gilbertsen,et al.  Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitor , 1987, Agents and Actions.

[29]  H. Simmonds,et al.  Central nervous system dysfunction and erythrocyte guanosine triphosphate depletion in purine nucleoside phosphorylase deficiency. , 1987, Archives of disease in childhood.

[30]  R. Lewis,et al.  The metabolism of deoxyguanosine in mitochondria: a characterization of the phosphorylation process which occurs in intact mitochondria. , 1987, Biochimica et biophysica acta.

[31]  B. Mitchell,et al.  Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective toxicity for T lymphoblasts. , 1981, Science.

[32]  W. Plunkett,et al.  Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy. , 1980, Cancer research.

[33]  R. Lewis,et al.  Partial purification and characterization of deoxyguanosine kinase from pig skin. , 1979, The Biochemical journal.

[34]  J. Kaye,et al.  Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[35]  P. Daddona,et al.  Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Kaye,et al.  Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. K. Wadman,et al.  Purine nucleoside phosphorylase deficiency associated with selective cellular immunodeficiency. , 1977, The New England journal of medicine.

[38]  D. Martin,et al.  Abnormal purine metabolism and purine overproduction in a patient deficient in purine nucleoside phosphorylase. , 1976, The New England journal of medicine.

[39]  A. Ammann,et al.  NUCLEOSIDE-PHOSPHORYLASE DEFICIENCY IN A CHILD WITH SEVERELY DEFECTIVE T-CELL IMMUNITY AND NORMAL B-CELL IMMUNITY , 1975, The Lancet.

[40]  G. Hitchings,et al.  Inhibition of human purine nucleoside phosphorylase. Studies with intact erythrocytes and the purified enzyme. , 1968, The Journal of biological chemistry.

[41]  S. Cha,et al.  Purine nucleoside phosphorylase from human erythrocytes. I. Purification and properties. , 1968, The Journal of biological chemistry.

[42]  T. Krenitsky.  Purine nucleoside phosphorylase: kinetics, mechanism, and specificity. , 1967, Molecular pharmacology.

[43]  P. Reichard,et al.  Ribonucleotide reductases. , 1998, Annual review of biochemistry.

[44]  M. Markert,et al.  Purine nucleoside phosphorylase deficiency , 2020, Atlas of Inherited Metabolic Diseases.

[45]  Charles R.scriver,et al.  The Metabolic basis of inherited disease , 1989 .

[46]  S. K. Wadman,et al.  Mechanisms of deoxyguanosine toxicity for human T and B lymphocytes. , 1986, Advances in experimental medicine and biology.

[47]  R. Parks,et al.  Purine Nucleoside Phosphorylase , 1985 .

[48]  E. Gelfand,et al.  Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. , 1983, Blood.

[49]  E. Gelfand,et al.  Biochemistry of diseases of immunodevelopment. , 1981, Annual review of biochemistry.